Classifications

• • A—HUMAN NECESSITIES
  • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
  • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
  • A01N59/00—Biocides, pest repellants or attractants, or plant growth regulators containing elements or inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K33/00—Medicinal preparations containing inorganic active ingredients
  • A61K33/20—Elemental chlorine; Inorganic compounds releasing chlorine
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/02—Inorganic compounds
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/04—Antibacterial agents
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
  • A61P31/10—Antimycotics
• • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
  • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
  • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
  • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
  • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

• Gram-positive bacteria and/or Gram-negative bacteria which are normally present in the intestine, can cross the intestinal wall and reach the circulation.
• conditions such as fasting and ischaemia can be present which facilitate the bacterial translocation.
• the surgical procedure itself may result in a disrupted intestinal barrier, particularly during abdominal surgery.
• This translocation results in short and midterm complications including sepsis, bacteraemia, and endotoxaemia.
• Peritonitis which is an inflammation of the peritoneum, also can result as a consequence of infection by microorganisms residing within the intestines which can be released during a surgical procedure.
• LPS lipopolysaccharide
• LTA lipoteichoic acid
• PG peptidoglycan
• the intestine is a reservoir of LPS and Gram-negative bacteria, such as the common inhabitant Escherichia coli, but also of LTA, PG and Gram-positive bacteria.
• LPS and Gram-negative bacteria such as the common inhabitant Escherichia coli, but also of LTA, PG and Gram-positive bacteria.
• the presence of Gram-negative and/or gram-positive bacteria and/or LPS and/or LTA and/or PG in the gut does not create any issues for a healthy individual.
• this can become a problem.
• Sepsis bacteraemia and/or endotoxaemia lead to a prolonged hospital stay and thus increased costs and increased morbidity. It can also lead to multiple organ failure or even death. It is, therefore, of great importance to find a method to treat, and especially to prevent bacterial translocation and resulting infection during or shortly after surgery.
• the invention additionally provides a method of treating or preventing infection associated with abdominal surgery on a mammal, comprising administering to the mammal an effective amount of an antimicrobial solution comprising (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water.
• an antimicrobial solution comprising (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water.
• the invention provides an antimicrobial solution comprising, consisting essentially of, or consisting of (a) hypochlorous acid, (b) a divalent cation, (c) phosphate anion, and (d) water.
• the solution can contain hypochlorous acid in an amount bounded by any two of the aforementioned endpoints.
• the solution can contain about 10 mg/L to about 500 mg/L, about 10 mg/L to about 400 mg/L, about 10 mg/L to about 300 mg/L, about 10 mg/L to about 200 mg/L, about 20 mg/L to about 200 mg/L, about 30 mg/L to about 200 mg/L, about 40 mg/L to about 200 mg/L, about 50 mg/L to about 200 mg/L, about 50 mg/L to about 150 mg/L, or about 100 mg/L to about 150 mg/L of hypochlorous acid.
• phosphate anion increases the degradation rate of hypochlorous acid. It has been unexpectedly found that the combination of divalent cation and phosphate anion allows for a reduction in the amount of phosphate anion required to provide a buffering action and further exhibits a significantly reduced rate of hypochlorous acid degradation.
• the antimicrobial solution of the present invention is generally stable for at least twenty-hours, and typically at least two days. More typically, the solution is stable for at least one week (e.g., one week, two weeks, three weeks, four weeks, etc.), and preferably at least two months. More preferably, the solution is stable for at least six months after its preparation. Even more preferably, the solution is stable for at least one year, and most preferably for at least three years.
• the solution is stable for at least twenty-hours, and typically at least two days. More typically, the solution is stable for at least one week (e.g., one week, two weeks, three weeks, four weeks, etc.), and preferably at least two months. More preferably, the solution is stable for at least six months after its preparation. Even more preferably, the solution is stable for at least one year, and most preferably for at least three years.
• the antimicrobial solution is capable of yielding at least a four log (10 4 ) reduction in total organism concentration following exposure for one minute, when measured at least two months after preparation of the solution.
• the solution is capable of such a reduction of organism concentration when measured at least six months after preparation of the solution. More preferably, the solution is capable of such a reduction of organism concentration when measured at least one year after preparation, and most preferably when measured at least three years after preparation.
• the invention also provides a pharmaceutical composition
• a pharmaceutical composition comprising the antimicrobial solution and a pharmaceutically acceptable carrier.
• the antimicrobial solution can be administered alone or in combination with one or more pharmaceutically acceptable carriers, e.g., vehicles, adjuvants, excipients, diluents, combinations thereof, and the like, which are preferably compatible with one or more of the species that exist in the
• vol/vol by about 90% (vol/vol), by about 95% (vol/vol), or by 99% (vol./vol.) or more, depending on the therapeutic application and/or any other therapeutically relevant factors.
• the hypochlorous acid can be prepared using any suitable process as discussed herein in connection with the inventive antimicrobial solution.
• the hypochlorous acid can be prepared by adding chlorine to water.
• the hypochlorous acid can be prepared via electrochemical generation from an aqueous sodium chloride solution using a single chamber cell or using two- and three-chambered cells. In some embodiments, arrangements comprising multiple cells can be utilized to provide the hypochlorous acid.
• the antimicrobial solution of the present invention may be transferred to a sealed container for distribution and sale to end users such as, for example, health care facilities including hospitals, nursing homes, doctor offices, outpatient surgical centers, dental offices, and the like.
• a sealed container for distribution and sale to end users such as, for example, health care facilities including hospitals, nursing homes, doctor offices, outpatient surgical centers, dental offices, and the like.
• Any suitable sealed container may be used that maintains the sterility and stability of the antimicrobial solution held by the container.
• the container may be constructed of any material that is compatible with the solution and should be generally non-reactive so that the ions present in the solution do not react with the container to any appreciable extent.
• An antimicrobial solution prepared in accordance with an embodiment of the invention was tested against methicillin-resistant S. aureus (MRSA), E. coli, P. aeruginosa, Vancomycin-resistant Enterococcus, P. mirabilis, S. marcescens, and C. albicans.
• MRSA methicillin-resistant S. aureus
• E. coli E. coli
• P. aeruginosa Vancomycin-resistant Enterococcus
• P. mirabilis Vancomycin-resistant Enterococcus
• S. marcescens S. marcescens
• C. albicans C. albicans

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Veterinary Medicine (AREA)
• Public Health (AREA)
• Medicinal Chemistry (AREA)
• Pharmacology & Pharmacy (AREA)
• Inorganic Chemistry (AREA)
• Epidemiology (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Organic Chemistry (AREA)
• General Chemical & Material Sciences (AREA)
• Chemical Kinetics & Catalysis (AREA)
• Oncology (AREA)
• Communicable Diseases (AREA)
• Engineering & Computer Science (AREA)
• Pest Control & Pesticides (AREA)
• Plant Pathology (AREA)
• Agronomy & Crop Science (AREA)
• Dentistry (AREA)
• Wood Science & Technology (AREA)
• Zoology (AREA)
• Environmental Sciences (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Toxicology (AREA)
• Medicinal Preparation (AREA)

Priority Applications (6)

Applications Claiming Priority (2)

Related Child Applications (2)

Publications (1)

Family

ID=51934166

Family Applications (1)

Country Status (6)

Cited By (1)

Families Citing this family (7)

Citations (4)

Family Cites Families (11)

• 2014
  • 2014-05-22 MX MX2015016057A patent/MX373524B/es active IP Right Grant
  • 2014-05-22 WO PCT/US2014/039202 patent/WO2014190184A1/en not_active Ceased
  • 2014-05-22 EP EP14801652.0A patent/EP2999341B1/en not_active Not-in-force
  • 2014-05-22 JP JP2016515094A patent/JP6416227B2/ja not_active Expired - Fee Related
  • 2014-05-22 US US14/893,448 patent/US9918477B2/en active Active
  • 2014-05-22 CA CA2913137A patent/CA2913137A1/en not_active Abandoned
• 2018
  • 2018-03-20 US US15/926,927 patent/US10412969B2/en active Active

Patent Citations (4)

Also Published As

Similar Documents

Legal Events